Fluticasone propionate in chronic rhinosinusitis with nasal polyps (CRSwNP): an artificial intelligence-driven consensus

IntroductionFluticasone propionate (FP) is a topical corticosteroid used to treat rhinosinusitis with nasal polyposis (CRSwNP). However, the need for a consensus on its use stems from the increasing focus on optimizing topical therapies to improve clinical outcomes and minimize systemic side effects...

Full description

Saved in:
Bibliographic Details
Main Authors: Emilio Avallone, Raffaella Iannella, Antonella Di Lullo, Michele Grasso, Salvatore Musto, Enzo Piermichele Troncone, Giuseppe Tortoriello, Bernardino Cassiano, Simona Nappi, Gianluca Bava, Giovanna Piazzetta, Giovanni Tomacelli, Aurelio D’Ecclesia, Giacomo Spinato, Giacomo Matrone, Doriano Politi, Carlo De Luca, Claudio Caporale, Livio Presutti, Gabriele Molteni, Ernesto Pasquini, Francesco Panu, Simonetta Masieri, Stefano Di Girolamo, Giulio Cesare Passali, Luca de Campora, Giandomenico Maggiore, Domenico Di Maria
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Allergy
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/falgy.2025.1594655/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850108465831215104
author Emilio Avallone
Raffaella Iannella
Antonella Di Lullo
Michele Grasso
Salvatore Musto
Enzo Piermichele Troncone
Giuseppe Tortoriello
Bernardino Cassiano
Simona Nappi
Gianluca Bava
Giovanna Piazzetta
Giovanni Tomacelli
Aurelio D’Ecclesia
Giacomo Spinato
Giacomo Matrone
Doriano Politi
Carlo De Luca
Claudio Caporale
Livio Presutti
Livio Presutti
Gabriele Molteni
Gabriele Molteni
Ernesto Pasquini
Francesco Panu
Simonetta Masieri
Stefano Di Girolamo
Giulio Cesare Passali
Luca de Campora
Giandomenico Maggiore
Domenico Di Maria
author_facet Emilio Avallone
Raffaella Iannella
Antonella Di Lullo
Michele Grasso
Salvatore Musto
Enzo Piermichele Troncone
Giuseppe Tortoriello
Bernardino Cassiano
Simona Nappi
Gianluca Bava
Giovanna Piazzetta
Giovanni Tomacelli
Aurelio D’Ecclesia
Giacomo Spinato
Giacomo Matrone
Doriano Politi
Carlo De Luca
Claudio Caporale
Livio Presutti
Livio Presutti
Gabriele Molteni
Gabriele Molteni
Ernesto Pasquini
Francesco Panu
Simonetta Masieri
Stefano Di Girolamo
Giulio Cesare Passali
Luca de Campora
Giandomenico Maggiore
Domenico Di Maria
author_sort Emilio Avallone
collection DOAJ
description IntroductionFluticasone propionate (FP) is a topical corticosteroid used to treat rhinosinusitis with nasal polyposis (CRSwNP). However, the need for a consensus on its use stems from the increasing focus on optimizing topical therapies to improve clinical outcomes and minimize systemic side effects.Materials and methodsThe Butterfly Decisions AI platform facilitated the collection and integration of evaluations and feedback, facilitating an expert consensus on 13 statements.ResultsThe participants agreed highly on the different statements. The experts agreed that FP effectively reduces the need for surgery and controls the symptoms of CRSwNP. The use of advanced delivery systems significantly improved drug delivery and therapeutic outcomes. Treatment with FP was associated with a reduction in the recurrence of nasal polyps and an improvement in the patient's quality of life.ConclusionsFP, as other equal corticosteroids, represents a first-line local therapy for patients with CRSwNP without complicating comorbidities due to its high efficacy and low systemic bioavailability. The Butterfly Decisions platform has demonstrated the effectiveness of integrating AI tools into clinical decision-making, improving the transparency and objectivity of assessments.
format Article
id doaj-art-3948da8dc6644fdfa4a150a338ba61fc
institution OA Journals
issn 2673-6101
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Allergy
spelling doaj-art-3948da8dc6644fdfa4a150a338ba61fc2025-08-20T02:38:21ZengFrontiers Media S.A.Frontiers in Allergy2673-61012025-05-01610.3389/falgy.2025.15946551594655Fluticasone propionate in chronic rhinosinusitis with nasal polyps (CRSwNP): an artificial intelligence-driven consensusEmilio Avallone0Raffaella Iannella1Antonella Di Lullo2Michele Grasso3Salvatore Musto4Enzo Piermichele Troncone5Giuseppe Tortoriello6Bernardino Cassiano7Simona Nappi8Gianluca Bava9Giovanna Piazzetta10Giovanni Tomacelli11Aurelio D’Ecclesia12Giacomo Spinato13Giacomo Matrone14Doriano Politi15Carlo De Luca16Claudio Caporale17Livio Presutti18Livio Presutti19Gabriele Molteni20Gabriele Molteni21Ernesto Pasquini22Francesco Panu23Simonetta Masieri24Stefano Di Girolamo25Giulio Cesare Passali26Luca de Campora27Giandomenico Maggiore28Domenico Di Maria29Department of Otolaryngology, AORN “San Pio”, Benevento, ItalyDepartment of Otolaryngology, AORN “San Pio”, Benevento, ItalyDepartment of Otolaryngology, AORN “San Pio”, Benevento, ItalyDepartment of Otolaryngology, AORN “San Pio”, Benevento, ItalyDepartment of Otolaryngology, AORN “San Pio”, Benevento, ItalyCEO, Butterfly Decisions S.r.l., Salerno, ItalyDepartment of Otolaryngology, AORN “Ospedale dei Colli”, Napoli, ItalyDepartment of Otolaryngology, Asl NA 3- Nola (NA), Nola, ItalyDepartment of Otolaryngology, Asl NA 3- Nola (NA), Nola, ItalySimple Departmental Operational Unit of ENT, G. Paolo II Hospital - Lamezia Terme (CZ), Lamezia Terme, ItalyDepartment of Medical and Surgical Sciences, Department of Otolaryngology, “Renato Dulbecco” University Hospital, Catanzaro, ItalyDepartment of General and Specialized Surgery, Department of Otolaryngology, ASL Lecce Vito Fazzi Hospital, Lecce, ItalyDepartment of Otolaryngology, Irccs Casa Sollievo Della Sofferenza San Giovanni Rotondo, Foggia, ItalyDepartment of Neurosciences, Otolaryngology Unit, University of Padova, Padova, Italy0Head of Data Science and AI, Butterfly Decisions, Salerno, Italy1Department of Otolaryngology, “Ospedale Dell’Angelo Mestre ULSS3 Serenissima”, Mestre, Italy2Fisioter Medical Center, ENT Division, Montecilfone Campobasso, Italy3Department of Otolaryngology, “Santo Spirito Hospital”, Pescara, Italy4Department of Otolaryngology-Head and Neck Surgery, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy5Alma Mater Studiorum-Università di Bologna, Bologna, Italy4Department of Otolaryngology-Head and Neck Surgery, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy5Alma Mater Studiorum-Università di Bologna, Bologna, Italy6Department of Specialist Surgery, ENT Unit, “Bellaria” Hospital, Bologna, Italy7Department of Otolaryngology, Policlinico Città di Quartu, Korian Kinetica Sardegna, Quartu, Italy8Scienze Odontostomatologiche e Maxillo Facciale Department, Sapienza University, Roma, Italy9Otolaryngology Department, Tor Vergata University, Rome, Italy0Unit of Otorhinolaryngology and Head-Neck Surgery, “A. Gemelli” Hospital Foundation IRCCS, Rome, Italy1Department of Otolaryngology, Azienda Ospedaliera S. Giovanni Addolorata, Roma, Italy2Department Otolaryngology Head and Neck Surgery, AOU Careggi Firenze, Firenze, ItalyDepartment of Otolaryngology, AORN “San Pio”, Benevento, ItalyIntroductionFluticasone propionate (FP) is a topical corticosteroid used to treat rhinosinusitis with nasal polyposis (CRSwNP). However, the need for a consensus on its use stems from the increasing focus on optimizing topical therapies to improve clinical outcomes and minimize systemic side effects.Materials and methodsThe Butterfly Decisions AI platform facilitated the collection and integration of evaluations and feedback, facilitating an expert consensus on 13 statements.ResultsThe participants agreed highly on the different statements. The experts agreed that FP effectively reduces the need for surgery and controls the symptoms of CRSwNP. The use of advanced delivery systems significantly improved drug delivery and therapeutic outcomes. Treatment with FP was associated with a reduction in the recurrence of nasal polyps and an improvement in the patient's quality of life.ConclusionsFP, as other equal corticosteroids, represents a first-line local therapy for patients with CRSwNP without complicating comorbidities due to its high efficacy and low systemic bioavailability. The Butterfly Decisions platform has demonstrated the effectiveness of integrating AI tools into clinical decision-making, improving the transparency and objectivity of assessments.https://www.frontiersin.org/articles/10.3389/falgy.2025.1594655/fullCRSwNPfluticasonebutterflyconsensusnasal drops
spellingShingle Emilio Avallone
Raffaella Iannella
Antonella Di Lullo
Michele Grasso
Salvatore Musto
Enzo Piermichele Troncone
Giuseppe Tortoriello
Bernardino Cassiano
Simona Nappi
Gianluca Bava
Giovanna Piazzetta
Giovanni Tomacelli
Aurelio D’Ecclesia
Giacomo Spinato
Giacomo Matrone
Doriano Politi
Carlo De Luca
Claudio Caporale
Livio Presutti
Livio Presutti
Gabriele Molteni
Gabriele Molteni
Ernesto Pasquini
Francesco Panu
Simonetta Masieri
Stefano Di Girolamo
Giulio Cesare Passali
Luca de Campora
Giandomenico Maggiore
Domenico Di Maria
Fluticasone propionate in chronic rhinosinusitis with nasal polyps (CRSwNP): an artificial intelligence-driven consensus
Frontiers in Allergy
CRSwNP
fluticasone
butterfly
consensus
nasal drops
title Fluticasone propionate in chronic rhinosinusitis with nasal polyps (CRSwNP): an artificial intelligence-driven consensus
title_full Fluticasone propionate in chronic rhinosinusitis with nasal polyps (CRSwNP): an artificial intelligence-driven consensus
title_fullStr Fluticasone propionate in chronic rhinosinusitis with nasal polyps (CRSwNP): an artificial intelligence-driven consensus
title_full_unstemmed Fluticasone propionate in chronic rhinosinusitis with nasal polyps (CRSwNP): an artificial intelligence-driven consensus
title_short Fluticasone propionate in chronic rhinosinusitis with nasal polyps (CRSwNP): an artificial intelligence-driven consensus
title_sort fluticasone propionate in chronic rhinosinusitis with nasal polyps crswnp an artificial intelligence driven consensus
topic CRSwNP
fluticasone
butterfly
consensus
nasal drops
url https://www.frontiersin.org/articles/10.3389/falgy.2025.1594655/full
work_keys_str_mv AT emilioavallone fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT raffaellaiannella fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT antonelladilullo fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT michelegrasso fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT salvatoremusto fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT enzopiermicheletroncone fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT giuseppetortoriello fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT bernardinocassiano fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT simonanappi fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT gianlucabava fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT giovannapiazzetta fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT giovannitomacelli fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT aureliodecclesia fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT giacomospinato fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT giacomomatrone fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT dorianopoliti fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT carlodeluca fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT claudiocaporale fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT liviopresutti fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT liviopresutti fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT gabrielemolteni fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT gabrielemolteni fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT ernestopasquini fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT francescopanu fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT simonettamasieri fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT stefanodigirolamo fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT giuliocesarepassali fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT lucadecampora fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT giandomenicomaggiore fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus
AT domenicodimaria fluticasonepropionateinchronicrhinosinusitiswithnasalpolypscrswnpanartificialintelligencedrivenconsensus